Publications by authors named "Milind M Javle"

Claim this Profile
G
Genomic Profiling of Indian Gallbladder Carcinoma: Mutational Insights in a High-Incidence Population.
Moushumi Suryavanshi, Vikas Ostwal, Milind M Javle, Manoj Kumar, Omshree Shetty

JCO Glob Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicogenomic Characterization of Primary Sclerosing Cholangitis-Associated Biliary Tract Cancers.
Xin Wang, Jaime Ivan Haro-Silerio, Felix Emile Gastonguay Beaudry, Ayelet Borgida, Farnoosh Abbas-Aghababazadeh, Milind M Javle

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.
Taiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav, Aysegul A Sahin, Hui Chen, Milind M Javle

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnic and socioeconomic disparities in survival outcomes among patients under 65 years with intrahepatic cholangiocarcinoma: a SEER analysis.
Adit Dharia, Lianchun Xiao, Janak Abraham, Fen Saj, Madhulika Eluri, Milind M Javle

J Gastrointest Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial.
Bruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, Brian M Anderson, Caleb S O'Connor, Milind M Javle

Lancet Gastroenterol Hepatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinic.
Elise Nassif Haddad, Milind M Javle, Timothy A Yap

Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
Rachna T Shroff, Gentry King, Sarah Colby, Aaron J Scott, Mitesh J Borad, Milind M Javle

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Sarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp, Milind M Javle

Oncologist· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Shishir K Maithel, Jessica M Keilson, Hop S Tran Cao, Manali Rupji, Amit Mahipal, Milind M Javle

Ann Surg Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Changhoon Yoo, Milind M Javle, Helena Verdaguer Mata, Filippo de Braud, Jörg Trojan

Hepatology· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.
Leontios Pappas, Islam Baiev, Stephanie Reyes, Andrea Grace Bocobo, Apurva Jain, Milind M Javle

JCO Precis Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial.
An T Ngo-Huang, Nathan H Parker, Lianchun Xiao, Keri L Schadler, Maria Q B Petzel, Milind M Javle

Ann Surg· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
Kristen Spencer, Leontios Pappas, Islam Baiev, Jordan Maurer, Andrea Grace Bocobo, Milind M Javle

J Natl Cancer Inst· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Filip Janku, Milind M Javle, Shiraj Sen, Shubham Pant, Lindsay G Bramwell

Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers.
Ashton A Connor, Sudha Kodali, Maen Abdelrahim, Milind M Javle, Elizabeth W Brombosz

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adopting Consensus Terms for Testing in Precision Medicine.
Nikki A Martin, Joel E Tepper, Veda N Giri, Thomas E Stinchcombe, Heather H Cheng, Milind M Javle

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Ian M Silverman, Meijuan Li, Karthikeyan Murugesan, Melanie A Krook, Milind M Javle

J Mol Diagn· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Andrew X Zhu, Teresa Macarulla, Milind M Javle, R Kate Kelley, Sam J Lubner

JAMA Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging.
Jane E Rogers, Jonathan D Mizrahi, Graciela M Nogueras Gonzalez, Rishi Surana, Rachna T Shroff, Milind M Javle

J Gastrointest Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Chirayu Mohindroo, Merve Hasanov, Jane E Rogers, Wenli Dong, Laura R Prakash, Milind M Javle

Cancer Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
Karthikeyan Murugesan, Radwa Sharaf, Meagan Montesion, Jay A Moore, James Pao, Milind M Javle

JCO Precis Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next generation sequencing for biliary tract cancers.
Timothy P DiPeri, Milind M Javle, Funda Meric-Bernstam

Expert Rev Gastroenterol Hepatol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
Jane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, Chirayu Mohindroo, Rachna T Shroff, Milind M Javle

Cancer Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner

Lancet Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia.
Jane E Rogers, Jonathan D Mizrahi, Rachna T Shroff, Douglas A Nelson, Janet Tu, Milind M Javle

J Gastrointest Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis